Imtiaz Ahmed, M.D.
NPI 1922071158 · Specialist · Kissimmee, FL
Enrolled with Medicare as Practitioner - Allergy/Immunology · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1922071158
- Entity type
- Individual
- Primary specialty
- SpecialistOther Service Providers
- Credential
- M.D.
- Sex
- Male
- Sole proprietor
- Yes
- License
- ME0058868 (FL)
Specialties & taxonomies
Other Service Providers
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
20 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
4,657 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Test for Allergy Using Allergenic Extract95004 | 2,075 | $4 |
| Professional Service for Preparation and Provision of 1 Or More Antigens95165 | 789 | $14 |
| Professional Service for Multiple Injections of Allergen95117 | 757 | $11 |
| Professional Service for Single Injection of Allergen95115 | 355 | $10 |
| Test for Allergy Using Allergenic Extract Injected Into Skin95024 | 229 | $8 |
| Administration of Non-Hormonal Anti-Neoplastic Chemotherapy Under Skin Or Into Muscle96401 | 182 | $61 |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 43 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Montelukast Sodium | 555 | 212 |
| Levocetirizine Dihydrochloride | 364 | 139 |
| Fluticasone Propionate | 227 | 105 |
| Omalizumabbrand: Xolair | 152 | 21 |
| Azelastine Hcl | 108 | 52 |
| Fluticasone/Umeclidin/Vilanterbrand: Trelegy Ellipta | 102 | 34 |
| Albuterol Sulfatebrand: Albuterol Sulfate Hfa |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$624 across 28 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2006-02-08
- Last updated
- 2016-06-09
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.